Urologie pro praxi 2/2018

Effectiveness and safety of abiraterone acetate treatment for metastatic castration-resistant prostate cancer post-chemotherapy

Castration resistant prostate cancer (CRPC) is an advanced stage of this disease with a significant impact on patients quality of life and unfavourable prognosis. Docetaxel chemotherapy is considered a standart treatment. Further treatment options in case of disease progression after chemotherapy are very limited. Cytochrome P-450 c17 inhibitor, abiraterone acetate (AA) is a novel drug used in second line treatment of CRPC. In this article we present results of international clinical studies evaluating efficiency and safety of AA treatment. According to these studies AA together with prednisone significantly improves median overall survival, time to prostate-specific antigen (PSA) progression and radiological progression, in comparison with prednisone alone. Treatment with AA and prednisone in metastatic CRPC has good efficacy with favourable safety profile.

Keywords: abiraterone acetate, castration-resistant prostate cancer.